Purpose: To assess prospectively the prognostic value of FDG PET/CT during curative-intent radiotherapy (RT) with or without concomitant chemotherapy in patients with non-small-cell lung cancer (NSCLC).

Methods: Patients with histological proof of invasive localized NSCLC and evaluable tumour, and who were candidates for curative-intent radiochemotherapy (RCT) or RT were preincluded after providing written informed consent. Definitive inclusion was conditional upon significant FDG uptake before RT (PET₁). All included patients had a FDG PET/CT scan during RT (PET₂, mean dose 43 Gy) and were evaluated by FDG PET/CT at 3 months and 1 year after RT. The main endpoint was death (from whatever cause) or tumour progression at 1 year.

Results: Of 77 patients preincluded, 52 were evaluable. Among the evaluable patients, 77% received RT with induction chemotherapy and 73% RT with concomitant chemotherapy. At 1 year, 40 patients (77 %) had died or had tumour progression. No statistically significant association was found between stage (IIIB vs. other), histology (squamous cell carcinoma vs. other), induction or concomitant chemotherapy, and death/tumour progression at 1 year. The SUVmax in the PET2 scan was the single variable predictive of death or tumour progression at 1 year (odds ratio 1.97, 95% CI 1.25 - 3.09, p = 0.003) in multivariate analysis. The area under the receiver operating characteristic curve was 0.85 (95% CI 0.73 - 0.94, p < 10(-4)). A SUVmax value of 5.3 in the PET₂ scan yielded a sensitivity of 70% and a specificity of 92% for predicting tumour progression or death at 1 year.

Conclusion: This prospective multicentre study demonstrated the prognostic value in terms of disease-free survival of SUVmax assessed during the 5th week of curative-intent RT or RCT in NSCLC patients (NCT01261598; RTEP2 study).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-014-2687-9DOI Listing

Publication Analysis

Top Keywords

fdg pet/ct
12
concomitant chemotherapy
12
tumour progression
12
non-small-cell lung
8
lung cancer
8
death tumour
8
progression year
8
patients
7
fdg
5
year
5

Similar Publications

Desmoplastic malignant peritoneal mesothelioma (DMPM) is an extremely rare and aggressive subtype of sarcomatoid malignant mesothelioma, originating from the mesothelial lining of body cavities. It is characterized by significant local invasiveness and poor prognosis. The nonspecific symptoms of DMPM often result in delayed diagnosis.

View Article and Find Full Text PDF

Neuroendocrine tumors (NETs) of the biliary tract are extremely rare due to a paucity of Kulchitsky cells. While their preoperative diagnosis remains challenging due to the lack of specific diagnostic markers and imaging findings, there have been no detailed reports describing the diagnostic utility of various imaging modalities for bile duct NETs at the junction of the cystic and common hepatic ducts. We report a case of a woman in her 40s who presented with jaundice and elevated hepatobiliary enzymes.

View Article and Find Full Text PDF

Purpose: CD38 is a glycoprotein highly specific to multiple myeloma (MM). Therapeutics using antibodies targeting CD38 have shown promising efficacy. However, the efficient stratification of patients who may benefit from daratumumab (Dara) therapy and timely monitoring of therapeutic responses remain significant clinical challenges.

View Article and Find Full Text PDF

Primary Retroperitoneal Seminoma-An Uncommon Presentation With Significant Implications.

Case Rep Surg

December 2024

Institute of Surgical Gastroenterology, GI and HPB Oncosurgery and Liver Transplant, Sir Ganga Ram Hospital, New Delhi, India.

Primary retroperitoneal seminoma is an exceedingly rare type of germ cell tumor, accounting for less than 5% of all such tumors. These tumors are typically large at presentation due to their slow growth and the nonspecific nature of symptoms, which often leads to delayed diagnosis. A 40-year-old male presented with intermittent abdominal pain and a palpable lump in the right paraumbilical region.

View Article and Find Full Text PDF

Objectives: The objective of this study was to evaluate the predictive value of F-fluorodeoxyglucose [F]FDG positron emission tomography (PET-CT) radiomic parameters in relation to KRAS/BRAF/EGFR mutations in patients with metastatic colorectal cancer (mCRC).

Methods: Blood samples were collected from 90 mCRC patients to assess KRAS G13V, BRAF V600E, and EGFR exon 20 mutations. [F]FDG PET-CT scans were performed, and radiomic parameters, including the SUV max, max TBR, total MTV, and total TLG, were calculated and correlated with different genotypes and haplotypes of the aforementioned mutations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!